期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

新型正性肌力药左西孟旦的作用机制及临床应用 被引量：9

Action mechanism and clinical application of new inotropic agent, levosimendan
原文传递
导出
摘要 左西孟旦是一种新型正性肌力药——钙增敏剂，可通过钙敏作用增强心肌收缩力，激活K^＋通道使血管扩张，且并不增加心肌氧耗和心率，因而具有改善心功能和心肌保护等作用。可应用于治疗急性失代偿心力衰竭、心肌缺血后心脏收缩力异常、心肌顿抑以及用于心脏手术期间循环的调控等方面。 Levosimendan, a new positive inotropic drug - Ca^2＋ sensitizer, enhances myocardial contractility by myocardial Ca^2＋ sensitization and dilates blood vessel by activating potassium channels, without changes in oxygen consumption and heart rate. Therefore, levosimendan may improve myocardial performance and exerts cardioprotective effects. Levosimendan has been used in patients with acute decompensation of chronic heart failure, myocardial infarction, contractile dysfunction after myocardial stunning. It is also used to regulate circulation in cardiac surgery.
作者 李玮伟 陈杰 王祥瑞
机构地区 上海交通大学医学院附属仁济医院麻醉科
出处 《国际麻醉学与复苏杂志》 CAS 2008年第6期517-519,523,共4页 International Journal of Anesthesiology and Resuscitation
关键词 左西孟旦 钙增敏剂 正性肌力药 治疗应用 levosimendan Ca^2＋ sensitizer inotropic agents therapeutic use
分类号 R96 [医药卫生—药理学] R614 [医药卫生—麻醉学]
  • 相关文献

参考文献21

  • 1Toller WG, Stranz C. Levosimendan, a new inotropic and vasodilator agent. Anesthesiology, 2006, 104: 556-569.
  • 2Haikala H, Nissinen E, Etemadzadeh E, et al. Troponin C-mediated calcium sensitization induced by levosimendan does not impair relaxation. J Cardiovasc Pharmacol, 1995, 25: 794-801.
  • 3Jonsson EN, Antila S, McFadyen L, et al. Population pharmaeokinetics of levosimcndan in patients with congestive heart failure. Br J Clin Pharmacol, 2003, 55: 544-551.
  • 4Antila S, Jarvinen A, Honkanen T, et al. Pharmacokinetic and pharmacodynamic interactions between the novel calcium sensitiser levosi- mendan and warfarin. Eur J Clin Pharmacol, 2000, 56: 705-710.
  • 5Kersten JR, Montgomery MW, Pagel PS, et al. Levosimendan, a new positive inotropic drug, decreases myocardial infarct size via activation of KATP channels. Anesth Analg, 2000, 90: 5-11.
  • 6Bowman P, Haikala H, Paul RJ. Levosimendan, a calcium sensitizer in cardiac muscle, induces relaxation in coronary smooth muscle through calcium desensitization. J Pharmacol Exp Ther, 1999, 288: 316-325.
  • 7Follath F, Cleland JG, Just H, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study) :a randomised double-blind trial. Lancet, 2002, 360: 196-202.
  • 8Moiseyev VS, Poder P, Andrejevs N, ct al. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction: a randomized, placebocontrolled, double-blind study (RUSSLAN). Eur Heart J, 2002, 23 : 1422-1432.
  • 9Busk M, Maeng M, Kristensen J, et al. Effects of levosimendan on myocardial infarct size and hemodynamics in a closed-chest porcine ischemia-reperfusion model. Cardiovasc Drugs Ther, 2006, 20: 335- 342.
  • 10Nieminen MS, Bohm M, Cowie MR, et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the task force on acule heart failure of the european society of cardiology. EurHeart J, 2005, 26: 384-416.

同被引文献66

  • 1金鸣,蔡亚欣,李金荣,赵辉.邻二氮菲－Fe^（2＋）氧化法检测H_2O_2／Fe^（2＋）产生的羟自由基[J].生物化学与生物物理进展,1996,23(6):553-555. 被引量：568
  • 2金雄哲,金政.何首乌对缺氧培养心肌细胞保护作用的实验研究[J].时珍国医国药,2006,17(8):1454-1456. 被引量：11
  • 3姜玉顺.体外培养心肌细胞的初步观察.延边医学院学报,1982,5(2):75-77.
  • 4周占林,徐坚,王宁夫,等.心肺运动试验对冠心病的诊断价值[C].2009年钱江国际心血管病会议暨浙江省心血管病年会论文汇编,2009:18-19.
  • 5Nieminen M. Levosimendan in Patients with Left Heart Failure After Acute Myocardial Infarction-Review of the RUSSLAN Study and Future Developments with Levosimendan. J Fur Kardiol, 2011,9 ( 3 ) :45-48.
  • 6Dao Q, Krishnaswamy P, Kazanegra R, et al. Utilty of B-rype natriuretic peptide in the diagnosis of congestive heart failure from lung disease in patients presenting with dyspnea. J Am Coil Cardial, 2001,37(2) :379-385.
  • 7Nieminen M. Levosimendan in patients with left heart failure after acute myocardial infarction -review of the russian study and future developments With levosimendan [ J ]. Journal Fiir Kardiologie, 2011,9(10): 4548.
  • 8Mcmurray JJ, Adamopoulos S, Anker SD,et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Di- agnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. De- veloped in collaboration with the Heart Failure Associa- tion (HFA) of the ESC[J]. Eur J Heart Fail,2012,14 (8) :803- 869.
  • 9Rognoni A, Lupi A, Lazzero M, et al. Levosimendan: from basic science to clinical trials[J]. Recent Pat Card- iovasc Drug Discov, 2011,6 ( 1 ) : 9-15.
  • 10McCann P, Hauptman PJ. Inotropic therapy., an im- portant role in the treatment of advanced symptomatic heart failure[J]. Med Clin North Am, 2012,96 (5) . 943-954.

引证文献9

二级引证文献74

国际麻醉学与复苏杂志
2008年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部